MGRX vs. TOI, CCM, PMD, MRAI, ATIP, BRTX, KDLY, ATPC, OTRK, and OPGN
Should you be buying Mangoceuticals stock or one of its competitors? The main competitors of Mangoceuticals include Oncology Institute (TOI), Concord Medical Services (CCM), Psychemedics (PMD), Marpai (MRAI), ATI Physical Therapy (ATIP), BioRestorative Therapies (BRTX), Kindly MD (KDLY), Agape ATP (ATPC), Ontrak (OTRK), and OpGen (OPGN). These companies are all part of the "healthcare" industry.
Mangoceuticals vs.
Mangoceuticals (NASDAQ:MGRX) and Oncology Institute (NASDAQ:TOI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership and dividends.
In the previous week, Mangoceuticals' average media sentiment score of 1.00 beat Oncology Institute's score of -0.86 indicating that Mangoceuticals is being referred to more favorably in the media.
Oncology Institute received 4 more outperform votes than Mangoceuticals when rated by MarketBeat users.
Oncology Institute has a consensus price target of $2.50, indicating a potential upside of 354.55%. Given Oncology Institute's stronger consensus rating and higher probable upside, analysts clearly believe Oncology Institute is more favorable than Mangoceuticals.
56.7% of Mangoceuticals shares are owned by institutional investors. Comparatively, 36.9% of Oncology Institute shares are owned by institutional investors. 39.3% of Mangoceuticals shares are owned by company insiders. Comparatively, 9.5% of Oncology Institute shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Mangoceuticals has a beta of 1.94, meaning that its stock price is 94% more volatile than the S&P 500. Comparatively, Oncology Institute has a beta of 0.13, meaning that its stock price is 87% less volatile than the S&P 500.
Oncology Institute has a net margin of -17.63% compared to Mangoceuticals' net margin of -1,237.00%. Mangoceuticals' return on equity of -138.00% beat Oncology Institute's return on equity.
Mangoceuticals has higher earnings, but lower revenue than Oncology Institute. Oncology Institute is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Mangoceuticals and Oncology Institute tied by winning 8 of the 16 factors compared between the two stocks.
Get Mangoceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MGRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mangoceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:MGRX) was last updated on 1/20/2025 by MarketBeat.com Staff
Free MGRX Stock Alerts